Tirabrutinib

Name: Tirabrutinib in Primary central nervous system lymphoma: American hospital formulary service (AHFS), or other drug classification
Published: 2026-09-14T15:39:06-04:00

Primary central nervous system lymphoma

Manufacturer: Deciphera Pharmaceuticals
Regulatory submission: NDA submitted December 2025
Launch: Anticipated in the fiscal year ending March 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information

American hospital formulary service (AHFS), or other drug classification

1 evidence topic · 1 source

ATC classification

“L01EL06 Tirabrutinib” (opens the source at this quote in a new tab)
“L01EL Bruton's tyrosine kinase (BTK) inhibitors” (opens the source at this quote in a new tab)